Virbac announces the arrival of Canixin^® L, a new L2 Leptospirosis vaccine for dogs

Canixin^® L is an inactivated bacterial vaccine suspension specifically formulated to stimulate active
immunity in dogs against two critical serogroups of Leptospira interrogans: Canicola and
Icterohaemorrhagiae. Leptospirosis is a bacterial infection that can infect multiple species and is
zoonotic, meaning it has the potential to be transmitted to humans.

Licensed to reduce infection, clinical signs, kidney colonisation, renal lesions, and importantly,
shedding in the urine, Canixin^® L plays a crucial role in minimising the risk of the disease to both the
individual and other animals that may come into contact.

The vaccine is licensed for use in dogs from 8 weeks of age, with a second injection administered 3
to 4 weeks later. For the Canicola serogroup, Canixin^® L offers the highest level of protection,
including prevention of mortality.

Clinical signs of leptospirosis can vary widely, ranging from mild, non-specific illness to fatal
outcomes. Most commonly, signs manifest as acute kidney injuries and/or liver dysfunction. While
historically considered a ‘rural’ disease, current consensus indicates that all dogs are at risk
regardless of breed, age, geographic location, or lifestyle, with no specific lifestyle eliminating risk.

Exposure can occur through:

• Direct contact with wildlife (rodents) or their urine
• Indirect contact with contaminated soil, puddles, or bedding
• Social contact with other dogs

“We are pleased to be able to offer Canixin^® L, allowing those using Canixin^® DHPPi/L to vaccinate
with L2 only in the intermediate years.”, said Rain Beckles – Product Manager. “It also provides an
excellent opportunity for practices with clients specifically requesting an L2 vaccine.”

For more information on Canixin^® L or any other vaccine in the Virbac range, contact your Virbac
Territory Manager or Virbac directly Tel: 01359 243243 Email: enquiries@virbac.co.uk